Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

1.63
Delayed Data
As of May 20
 -0.04 / -2.40%
Today’s Change
1.26
Today|||52-Week Range
6.86
-56.53%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2015

2016

2017

2018
Revenue and IncomeNet Revenues16.8M14.1M38.2M59.4M
 
 
 
 
 
Depreciation And Amortization2.5M3.3M5.5M7.8M
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses70.0M83.1M123.9M150.9M
 
 
 
 
 
Research And Development50.2M63.3M98.1M115.2M
 
 
 
 
 
Total Operating Expenses72.5M86.4M129.4M158.7M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-55.7M-72.3M-91.1M-99.3M
 
 
 
 
 
Extraordinary Charge0.000.00-1.0M-209.6K
 
 
 
Other Expenses2.8M995.1K8.6M-15.5M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-26.2M-70.2M-81.3M-112.1M
 
 
 
 
 
Income Taxes-3.8M-885.8K-10.4M-16.8M
 
 
 
 
 
Net Income-22.4M-71.1M-70.9M-95.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS70.8M70.8M87.9M97.4M
 
 
 
 
 
Shares To Calculate EPS Diluted70.8M70.8M87.9M97.4M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.18-$1.01-$0.79-$0.98
 
 
 
 
 
EPS Diluted-$0.27-$1.01-$0.79-$0.98